Enveric Biosciences (ENVB) Cost of Revenue (2014 - 2020)

Enveric Biosciences has reported Cost of Revenue for 7 years, with the latest figure at $6.6 million in Q3 2020.

• Quarterly Cost of Revenue fell 9.02% year-over-year to $6.6 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $28.1 million (down 14.38% YoY) and the FY2019 annual result came in at $31.8 million, down 6.62% from the prior year.
• Cost of Revenue grew to $6.6 million in Q3 2020 per ENVB's latest filing, from $6.4 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $10.3 million in Q4 2016 and troughed at $1.9 million in Q1 2016.
• A 5-year average of $7.9 million and a median of $8.4 million in 2018 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2016 and 2017: Cost of Revenue slumped 39.99% in 2016, then surged 375.77% in 2017.
• Over 5 years, Cost of Revenue stood at $10.3 million in 2016, then fell by 8.78% to $9.4 million in 2017, then declined by 11.02% to $8.4 million in 2018, then decreased by 12.44% to $7.3 million in 2019, then decreased by 10.09% to $6.6 million in 2020.
• According to Business Quant data, Cost of Revenue over the past three periods registered $6.6 million, $6.4 million, and $7.7 million for Q3 2020, Q2 2020, and Q1 2020 respectively.